Why the IDT Australia (ASX:IDT) share price is crashing 37% lower today

IDT shares are being hammered today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is crashing down to Earth on Thursday morning.

At the time of writing, the pharmaceutical manufacturing company's shares are down 37% to 30 cents.

A woman screams and holds her hands up in frustration.

Image source: Getty Images

Why is the IDT Australia share price crashing today?

Investors have been selling down the IDT Australia share price today after it was dealt a bitter blow.

Earlier this year, the company announced that it successfully manufactured an mRNA drug product. This made IDT the first in Australia to manufacture a cGMP mRNA drug product.

In light of this, there were hopes that this would support its Australian Government Approach To Market submission to establish an onshore mRNA manufacturing capability (ATM).

However, this morning the Australian Government has confirmed that IDT's ATM submission has not been selected to progress to the next stage of the process.

IDT's CEO, Dr David Sparling, commented: "Whilst we are disappointed in the outcome of the ATM process, IDT has developed and progressed several alternative strategic options. The Company has successfully delivered on the Monash Institute of Pharmaceutical Sciences (MIPS) COVID-19 mRNA receptor binding domain vaccine candidate project, being Australia's first locally manufactured cGMP mRNA finished product and clearly showcases IDT's manufacturing capabilities in this regard."

What's next?

Dr Sparling notes that the company remains in the running for the Manufacturing Collaboration Stream Grant Opportunity.

"IDT is now sterile licenced and is maintaining its sterile facilities in a state of readiness to accept COVID-19 vaccine content at the Government's discretion. The Company is also waiting to receive feedback on its submission to the Australian Government's $800m Modern Manufacturing Initiative (MMI) Manufacturing Collaboration Stream Grant Opportunity," Dr Sparling added.

Positively, the company also stressed that the proposal is unaffected by the outcome of the ATM process. It will provide a market update if and when additional information comes to hand.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »